Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (43)COVID-19 (36)

Type

TypeGuidance (3882)Indicators (267)News (230)NICE advice (496)Quality standards (255)Research recommendations (1922)

Status

StatusAwaiting development (328)Discontinued (382)In consultation (6)In development (422)Published (2460)Topic selection (288)

Last updated

Last updatedLast 3 months (60)Last 6 months (142)Last year (584)Last 3 years (1774)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (25)Cancer service guidelines (10)Clinical guidelines (380)COVID-19 NHSE/I specialty guides (2)COVID-19 rapid guidelines (27)Diagnostics guidance (93)Health technology evaluations (38)Highly specialised technologies guidance (47)Interventional procedures guidance (950)Medical technologies guidance (154)Medicines practice guidelines (5)NICE guidelines (562)Public health guidelines (88)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2034)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)

Showing 6916 to 6930 of 7680 results

Sort by

Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]
Discontinued [GID-TAG410]
Result type
Technology appraisal guidance
Status
Discontinued
Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]
Discontinued [GID-TA10836]
Result type
Technology appraisal guidance
Status
Discontinued
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
Discontinued [GID-TA10768]
Result type
Technology appraisal guidance
Status
Discontinued
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
Discontinued [GID-TA10465]
Result type
Technology appraisal guidance
Status
Discontinued
Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]
Discontinued [GID-TA10875]
Result type
Technology appraisal guidance
Status
Discontinued
Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]
Discontinued [GID-TA10625]
Result type
Technology appraisal guidance
Status
Discontinued
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Discontinued [GID-TA10617]
Result type
Technology appraisal guidance
Status
Discontinued
Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]
Discontinued [GID-TA10634]
Result type
Technology appraisal guidance
Status
Discontinued
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
Discontinued [GID-TA10585]
Result type
Technology appraisal guidance
Status
Discontinued
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
Discontinued [GID-TA10492]
Result type
Technology appraisal guidance
Status
Discontinued
Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]
Discontinued [GID-TA10628]
Result type
Technology appraisal guidance
Status
Discontinued
Elotuzumab for untreated multiple myeloma [ID966]
Discontinued [GID-TA10134]
Result type
Technology appraisal guidance
Status
Discontinued
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
Discontinued [GID-TA10590]
Result type
Technology appraisal guidance
Status
Discontinued
Tanezumab for treating pain caused by bone metastases [ID3784]
Discontinued [GID-TA10922]
Result type
Technology appraisal guidance
Status
Discontinued
Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]
Discontinued [GID-TA10857]
Result type
Technology appraisal guidance
Status
Discontinued

Previous page
1
…
460
461
Current page 462
463
464
…
512
Page 462 of 512
Next page

Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Knowledge resources

About NICE
Into practice
Get involved with NICE
Jobs
News
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2024. All rights reserved. Subject to Notice of rights.